Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphoma

弥漫性大B细胞淋巴瘤 淋巴瘤 医学 内科学 美罗华 免疫组织化学 肿瘤科 生发中心 血液学 病理 抗体 B细胞 免疫学
作者
Yasuto Naoi,Ryota Chijimatsu,Takahiro Urata,Kazutaka Sunami,Tamaki Imai,Yukifumi Nawa,Yasushi Hiramatsu,Kazuhiko Yamamoto,Soichiro Fujii,Isao Yoshida,Tomonori Yano,Kazuhiro Ikeuchi,Hiroki Kobayashi,Kazutoshi Tani,Yasuharu Sato,M. Boyle,Aixiang Jiang,Yoshinobu Maeda,David W. Scott,Daisuke Ennishi
出处
期刊:Hematological Oncology [Wiley]
卷期号:41 (S2): 301-302
标识
DOI:10.1002/hon.3164_210
摘要

Introduction: CD79B is a target of polatuzumab vedotin, an antibody–drug conjugate, which may improve the prognosis of both previously untreated and relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL). However, the biological and clinical significance of CD79B protein and gene expression in DLBCL is largely unknown. Methods: We retrospectively analyzed de novo DLBCL patients, who were diagnosed and received rituximab-based immunochemotherapy from 2008 through 2018 in the Okayama Hematology Study Group from Japan. Immunohistochemistry (IHC) staining was performed using a CD79B antibody (AT107-2), and protein expression was assessed based on H-score according to a previous study (Sehn L et al. JCO 2020). We also performed gene expression profile-based cell-of-origin (COO) classification, including double-hit signature (DHITsig) which has been renamed to dark zone signature (DZsig) (Waleed A et al. Blood 2022), using the NanoString DLBCL90 assay. Results: CD79B IHC expression was evaluable in 602 cases. We idefined two groups according to median H-score of CD79B expression: CD79Bhigh and CD79Blow. The COO subtypes were assigned as follows: 308 patients (51%) with activated B-cell-like (ABC)-DLBCL, 196 (33%) with germinal center B-cell-like (GCB)-DLBCL, 32 (5%) with DZsig-pos DLBCL and 66 (11%) with unclassified (UNC). H-score of CD79B was the lowest in patients with ABC-DLBCL followed by GCB-DLBCL and DZsig-pos DLBCL in ascending order (Kruskal–Wallis test P < .00001; Figure A). Indeed, CD79Blow tumors were significantly enriched in ABC-DLBCL (57%) compared to GCB-DLBCL (40%) and DZsig-pos DLBCL (22%), respectively (both, P < .001). Consistently, using publicly available DLBCL datasets (Schmitz et al. NEJM 2018 and Ennishi et al. JCO 2019), we revealed that CD79B gene expression was the lowest in ABC-DLBCL compared to GCB- and DHITsig-DLBCL (Kruskal–Wallis test P = .01; Figure B and C). The association of CD79B expression with COO prompted us to evaluate CD79B expression in normal germinal center B cells. Notably single-cell transcriptomic analyses of six reactive lymphoid tissues from publicly available datasets revealed that the lowest expression of CD79B was found in plasmablasts followed by light zone B cells and dark zone B cells in ascending order (Kruskal–Wallis test P < .0001), supporting the differential expression of CD79Baccording to COO subtype. CD79Blow group had significantly shorter overall survival (OS) in the total DLBCL cohort (log-rank, P < .001) and within ABC-DLBCL (P = .001, Figure D and E). Moreover, CD79B protein expression was significantly associated with OS after adjusting for International Prognostic Index in the total cohort (Cox regression model; P< .001). Keywords: Aggressive B-cell non-Hodgkin lymphoma, Diagnostic and Prognostic Biomarkers Conflicts of interests pertinent to the abstract. K. Sunami Honoraria: Celgene, Sanofi, BMS, Ono, Janssen Research funding: Takeda, AbbVie, GSK, Chugai, Otsuka, MSD, Novartis, Astellas Amgen, Pfizer, Parexel, Kyowa Kirin, Symbio, Agios Y. Hiramatsu Honoraria: Chugai Pharmaceutical Co, Nippon Shinyaku Co, Bristol Myers Squibb, Sanofi K.K. I. Yoshida Honoraria: Kyowa Kirin, Chugai, Eisai, Jannsen, Nippon-shinyaku, Otsuka, Symbio, Takeda, Sumitomo Pharma, Meiji Research funding: Kyowa Kirin, Chugai Y. Maeda Research funding: Chugai, Nippon-shinyaku Other remuneration: Chugai, Eisai, Otsuka, Kyowa Kirin, Takeda D. W. Scott Consultant or advisory role: Abbvie, AstraZeneca, Janssen, Incyte Honoraria: AstraZeneca Research funding: Janssen, Roche/Genentech D. Ennishi Honoraria: Chugai, Eisai, Kyowa Kirin Research funding: Nipponshinyaku, Chugai
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
ercha发布了新的文献求助30
1秒前
kyran发布了新的文献求助10
1秒前
1秒前
科研通AI2S应助迷路的初柔采纳,获得10
2秒前
希望天下0贩的0应助烧酒采纳,获得30
2秒前
尽我所能完成签到,获得积分10
3秒前
kk完成签到,获得积分10
3秒前
Cartes完成签到,获得积分10
3秒前
3秒前
非哲完成签到 ,获得积分10
3秒前
CipherSage应助黑尼格采纳,获得10
3秒前
zyr完成签到,获得积分10
4秒前
4秒前
JUZI发布了新的文献求助10
4秒前
充电宝应助氮化碳采纳,获得10
4秒前
5秒前
长安完成签到,获得积分10
5秒前
尽我所能发布了新的文献求助10
5秒前
最後まで发布了新的文献求助10
6秒前
ll应助chen采纳,获得10
7秒前
1111应助我最好命采纳,获得20
7秒前
林林发布了新的文献求助40
7秒前
7秒前
七仔发布了新的文献求助10
8秒前
anny2022完成签到,获得积分10
8秒前
8秒前
Rosaline发布了新的文献求助10
8秒前
9秒前
9秒前
小蓬牖完成签到,获得积分10
10秒前
鲤鱼平安发布了新的文献求助10
10秒前
10秒前
dadadasds完成签到,获得积分10
11秒前
11秒前
demom完成签到 ,获得积分10
12秒前
在水一方应助hhhyyy采纳,获得10
12秒前
星辰大海应助细腻海蓝采纳,获得10
12秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969222
求助须知:如何正确求助?哪些是违规求助? 3514124
关于积分的说明 11171948
捐赠科研通 3249361
什么是DOI,文献DOI怎么找? 1794799
邀请新用户注册赠送积分活动 875431
科研通“疑难数据库(出版商)”最低求助积分说明 804779